View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 30, 2020

Moderna and UK sign deal to supply two million more Covid-19 vaccine doses

Moderna has signed an agreement with the UK Government to supply an additional two million doses of its Covid-19 vaccine candidate, mRNA-1273, from March next year.

Moderna has signed an agreement with the UK Government to supply an additional two million doses of its Covid-19 vaccine candidate, mRNA-1273, from March next year.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

With this deal, the UK secured a total of seven million doses of mRNA-1273.

The UK already secured five million doses of the vaccine candidate.

Co-developed by Moderna and NIAID Vaccine Research Center investigators, the mRNA vaccine candidate encodes for a prefusion stabilised form of the Spike (S) protein.

Moderna CEO Stéphane Bancel said: “We appreciate the collaboration with the UK government as with many other governments and other key partners around the world.

“We are proud of the progress on mRNA-1273 we have made to date including the positive interim analysis from our Phase III COVE study.”

On 16 November, Moderna reported that Phase III COVE study of mRNA-1273 showed the vaccine had an efficacy of 94.5%, meeting the statistical criteria pre-specified in the study protocol for efficacy.

The US study, conducted in partnership with National Institutes of Health (NIH) unit the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA), had over 30,000 participants.

Last month, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK initiated the rolling review process of mRNA-1273.

The company is working on increasing its global manufacturing in a bid to supply approximately 500 million doses per year and up to one billion annually from next year.

Alongside this, Moderna is also working on manufacturing and fill-finish of the vaccine outside of the US with its partners, Swiss company Lonza and Spanish firm ROVI.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology